Journal article
Dose response in the subthreshold nanosecond laser trial in early stages of AMD: A LEAD study report
AC Cohn, J Runciman, LAB Hodgson, E Caruso, JJ Arnold, FK Chen, U Chakravarthy, WJ Heriot, RH Guymer, Z Wu
Ophthalmic Surgery Lasers and Imaging Retina | Published : 2021
Abstract
BACKGROUND AND OBJECTIVE: To examine the association between treatment parameters and the progression to late age-related macular degeneration (AMD) in the Laser Intervention in Early Stages of Age-Related Macular Degeneration (LEAD) study, a randomized, controlled trial of a subthreshold nanosecond laser (SNL) for slowing disease progression in the early stages of AMD. PATIENTS AND METHODS: The association between treatment parameters early in the trial period for participants in the SNL arm of the LEAD study and time to develop late AMD during the 3-year trial duration was examined. Parameters included treatment energy at the baseline and 6-month visits and the number of laser spots visibl..
View full abstractGrants
Awarded by Pfizer
Funding Acknowledgements
Supported by National Health & Medical Research Council of Australia (project grant No. APP1027624 [RHG and CDL]); fellowship grants No. GNT1103013 (RHG), APP1104985 [ZW], APP1054712 [FKC], APP1142962 [FKC], and GNT1128343 [SSW]); and BUPA Health Foundation (Australia) (RHG and CDL). The Centre for Eye Research Australia (CERA) receives operational infrastructure support from the Victorian Government. Ellex R&D Pty Ltd (Adelaide, Australia) provided partial funding of the central coordinating center and the in-kind provision of Ellex 2RT laser systems, ongoing support of those systems, and the Macular Integrity Assessment micro-perimeters for the duration of the study. The web-based Research Electronic Data Capture (REDCap) application and open-source platform OpenClinica allowed secure electronic data capture. The study is sponsored by CERA, an independent medical research institute and a not-for-profit company. Dr. Cohn has received personal fees from Bayer and Novartis. Dr. Arnold has received personal fees from Alcon, Allergan, Bayer, and Novartis. Dr. Chen has received personal fees from Bayer, Novartis, Allergan, Heidelberg Engineering, Alcon, and Pfizer, as well as research grants from Novartis and Bayer, outside the submitted work. Dr. Chakravarthy has received personal fees and research grants from Bayer, Novartis, and Roche outside the submitted work. Dr. Heriot has received personal fees from Alcon, Bayer and Novartis outside the submitted work. Dr. Guymer has received personal fees from Bayer, Novartis, Roche Genentech, and Apellis, as well as a research grant from Bayer, outside the submitted work. Drs. Runciman, Hodgson, Caruso, and Wu report no relevant financial disclosures.